IDH1 and glioblastoma: This aligns with extensive prior evidence that IDH mutation is one of the strongest favorable prognostic factors in diffuse gliomas.[16] For example, IDH-mutant glioblastomas have a significantly higher median survival than IDH-wildtype glioblastomas, and the presence of an IDH mutation in lower-grade tumors portends a more indolent course.